These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Blume-Peytavi U; Hillmann K; Dietz E; Canfield D; Garcia Bartels N J Am Acad Dermatol; 2011 Dec; 65(6):1126-1134.e2. PubMed ID: 21700360 [TBL] [Abstract][Full Text] [Related]
30. Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male Androgenetic alopecia. Bao L; Gong L; Guo M; Liu T; Shi A; Zong H; Xu X; Chen H; Gao X; Li Y J Cosmet Laser Ther; 2020; 22(1):1-7. PubMed ID: 29028377 [No Abstract] [Full Text] [Related]
31. A randomized, placebo-controlled trial of 1% topical minoxidil solution in the treatment of androgenetic alopecia in Japanese women. Tsuboi R; Tanaka T; Nishikawa T; Ueki R; Yamada H; Katsuoka K; Ogawa H; Takeda K Eur J Dermatol; 2007; 17(1):37-44. PubMed ID: 17324826 [TBL] [Abstract][Full Text] [Related]
32. Oral minoxidil treatment for hair loss: A review of efficacy and safety. Randolph M; Tosti A J Am Acad Dermatol; 2021 Mar; 84(3):737-746. PubMed ID: 32622136 [TBL] [Abstract][Full Text] [Related]
33. The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review. Sung CT; Juhasz ML; Choi FD; Mesinkovska NA J Drugs Dermatol; 2019 Feb; 18(2):155-160. PubMed ID: 30794366 [TBL] [Abstract][Full Text] [Related]
34. Allergic Contact Dermatitis Due to Minoxidil in a Patient with Alopecia Areata. Navarro-Triviño FJ; Pegalajar-García MD; Gil-Villalba A; Ruiz-Villaverde R Actas Dermosifiliogr; 2022 Dec; 113 Suppl 1():S8-S9. PubMed ID: 36543468 [No Abstract] [Full Text] [Related]
35. [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study]. Piraccini B; Starace M; Alessandrini A; Guarrera M; Fiorucci MC; Lorenzi S G Ital Dermatol Venereol; 2011 Dec; 146(6 Suppl 1):1-8. PubMed ID: 22189834 [TBL] [Abstract][Full Text] [Related]
36. Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Goren A; Shapiro J; Roberts J; McCoy J; Desai N; Zarrab Z; Pietrzak A; Lotti T Dermatol Ther; 2015; 28(1):13-6. PubMed ID: 25112173 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study. Blume-Peytavi U; Issiakhem Z; Gautier S; Kottner J; Wigger-Alberti W; Fischer T; Hoffmann R; Tonner F; Bouroubi A; Voisard JJ J Cosmet Dermatol; 2019 Feb; 18(1):215-220. PubMed ID: 29659116 [TBL] [Abstract][Full Text] [Related]
38. Topical minoxidil: review of efficacy and safety. Katz HI Cutis; 1989 Jan; 43(1):94-8. PubMed ID: 2644080 [TBL] [Abstract][Full Text] [Related]
39. Extemporaneous Topical Minoxidil Solutions for the Treatment of Androgenetic Alopecia- Stability Studies and Incorporation Tests of Active Pharmaceutical Ingredients in Aloplus Total Base. Spennacchio A; Lopedota AA; Lopalco A; Cutrignelli A; la Forgia FM; Fontana S; Franco M; Denora N Int J Pharm Compd; 2024; 28(1):68-73. PubMed ID: 38306622 [TBL] [Abstract][Full Text] [Related]
40. Pustular allergic contact dermatitis from minoxidil. Sánchez-Motilla JM; Pont V; Nagore E; Rodríguez-Serna M; Sánchez JL; Aliaga A Contact Dermatitis; 1998 May; 38(5):283-4. PubMed ID: 9667450 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]